Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | Dr. Richard B. MarshakChief Commercial Officer | -543,00 | 1,45k | Vendita | 2,67 | 66,73k | -0,81% |
| 2026-05-15 | Ms. Mary T. SzelaCEO, President & Director | 39,68k | 102,78k | Acquisto | 2,59 | 433,57k | 10,07% |
| 2026-05-15 | Mr. Mats L. WahlstromIndependent Chairman | 60,00k | 151,80k | Acquisto | 2,53 | 1,52M | 4,11% |
| 2026-05-15 | Mr. Michael P. StanskyIndependent Director | 610,00k | 1,53M | Acquisto | 2,50 | 1,60M | 61,81% |
| 2026-05-15 | Dr. Gary B. GordonIndependent Director | 10,00k | 24,60k | Acquisto | 2,46 | 19,78k | 102,29% |
| 2026-05-15 | Mr. David B. PatienceCFO | 7,10k | 17,25k | Acquisto | 2,43 | 27,01k | 35,67% |
| 2025-07-31 | Frankenius Equity ABSocietà | 759,00k | 0,00 | Derivative Exercise and Retained Stock | - | 6,99M | 12,18% |
| 2025-07-31 | Mr. David J. MatlinIndependent Director | 330,00k | 0,00 | Derivative Exercise and Retained Stock | - | 1,27M | 35,03% |
| 2026-03-12 | Ms. Jennifer L. StevensChief Regulatory, Quality and Therapeutics Officer | -2,33k | 9,54k | Vendita | 4,09 - 4,12 | 77,61k | -2,91% |
| 2026-03-11 | Ms. Jennifer L. StevensChief Regulatory, Quality and Therapeutics Officer | -1,20k | 4,97k | Vendita | 4,13 | 77,61k | -1,53% |
| 2026-03-12 | Dr. Richard B. MarshakChief Commercial Officer | -2,01k | 8,23k | Vendita | 4,09 - 4,12 | 52,02k | -3,72% |
| 2026-03-11 | Dr. Richard B. MarshakChief Commercial Officer | -1,45k | 5,98k | Vendita | 4,13 | 52,02k | -2,71% |
| 2026-03-12 | Ms. Jodi DevlinInsider | -2,05k | 8,37k | Vendita | 4,09 - 4,12 | 50,18k | -3,92% |
| 2026-03-11 | Ms. Jodi DevlinInsider | -1,16k | 4,80k | Vendita | 4,13 | 50,18k | -2,26% |
| 2026-03-12 | Dr. Bryan F. CoxChief of Research | -2,05k | 8,39k | Vendita | 4,09 - 4,12 | 124,42k | -1,62% |
| 2026-03-11 | Dr. Bryan F. CoxChief of Research | -1,14k | 4,70k | Vendita | 4,13 | 124,42k | -0,91% |
| 2026-03-11 | Ms. Mary T. SzelaCEO, President & Director | -20,30k | 79,38k | Vendita | 3,85 - 4,13 | 365,04k | -5,27% |
| 2026-02-23 | Mr. David B. PatienceCFO | 3,66k | 14,99k | Acquisto | 4,10 | 19,91k | 22,50% |
| 2026-02-23 | Mr. William J. ValleIndependent Director | 30,49k | 125,00k | Acquisto | 4,10 | 30,49k | - |
| 2026-02-23 | Dr. Gary B. GordonIndependent Director | 9,76k | 40,00k | Acquisto | 4,10 | 9,76k | - |
| 2026-02-23 | Mr. Michael P. StanskyIndependent Director | 361,10k | 1,48M | Acquisto | 4,10 | 986,83k | 57,71% |
| 2026-02-23 | Ms. Mary T. SzelaCEO, President & Director | 30,49k | 125,00k | Acquisto | 4,10 | 407,42k | 8,09% |
| 2025-07-31 | Frankenius Equity ABSocietà | -230,00k | 0,00 | Other Disposition | - | - | - |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
